Clinical characteristics and persistence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG antibodies in 4,607 French healthcare workers: Comparison with European countries

As a response to the evolving information about the coronavirus disease 2019 (COVID-19) pandemic, health agencies and organizations have been updating guidelines for infection prevention and control. McMullen et al made some predictions about increasing and decreasing hospital-acquired infection rates due to the crisis for COVID-19. Despite the numerous control challenges posed by severe acute respiratory coronavirus virus (SARS-CoV-2) in acute-care facilities, in some ways, we have been able to identify some “ silver linings ” or opportunities for improved infection control practices amidst the pandemic.

To the Editor-The safety of healthcare workers (HCWs) is a major challenge for healthcare systems. In the course of a severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection, immunoglobulin G (IgG) antibodies may be detected after a median of 14-24 days (interquartile range [IQR], 10-18) after onset of symptoms. 1 In France, the coronavirus disease 2019 (COVID-19) pandemic reached a peak on April 7, 2020. HCWs had mobility and flexibility inside the Paris Center university hospital, where there was a cluster in the pandemic. We investigated the prevalence of IgG antibodies against SARS-CoV-2 among all HCWs in this hospital. We also sought to determine the correlation between RT-PCR test and serology and to compare our seroprevalence with that of other European countries.
From May 14, 2020, to June 17, 2020, all HCWs were asked by the occupational health department to participate in serologic screening. The Abbott-Architect test (Abbott Laboratories, Abbott Park, IL) was used to detect IgG anti-SARS-CoV-2. During blood sampling, clinical information was recorded using a standardized self-questionnaire on presented symptoms, comorbidities, and the reverse-transcriptase polymerase chain reaction (RT-PCR) test if one had been previously performed. Blood samples were collected >28 days after the first symptoms from those who were symptomatic.
The seroprevalence and 95% confidence interval were estimated using the Fisher exact method. The t test and the χ 2 test were performed to compare quantitative and qualitative variables, respectively. Simple and multivariate logistic regressions were performed to assess risk and symptoms associated with seroprevalence respectively. Statistical analyses were performed using SAS software (SAS Institute, Cary, NC). The local institutional review board approved this study. All subjects participated voluntarily under pseudonyms.
Of 5,021 workers present during the study period, 4,607 (91.8%) were included in the study. The mean age was 41.8 years (SD, 12.6), and 75% were female. Furthermore, 45% were paramedical staff members, 36% were physicians (including medical students), and 19% were in administrative and other professions.

Discordance between RT-PCR and serology
In our study, 19.4% of the study participants had had a RT-PCR. Among individuals with negative RT-PCR, 51 of 662 (7.7%) had detectable SARS-CoV-2 antibodies, whereas 29 of 233 (12.4%) of RT-PCR-positive participants also had no detectable antibodies. The former result could be explained either by difficulties implementing RT-PCR tests or by the delay between the time of the test and the effective date of infection. For the latter finding, in addition to participants who did not develop antibodies, the time lag between PCR and serology should be mentioned (mean, 64.0 days), which implies that the serology is often realized long after the IgG peak. Indeed, the mean of antibody prevalence in this group (0.28 ± 0.32) was higher than in the negative RT-PCR group (0.05 ± 0.08; P < .001). More generally, this group with positive RT-PCR and negative antibody tests had specific characteristics: younger age (38.3 ± 12.8 vs 43.3 ±12.4; P = .04), more likely a smoker (31.0% vs 7.4%; P < 10 -4 ), and male (37.9% vs 18.1%; P = .01) compared with those with positive RT-PCR and positive serology tests (Table S2).

Comparison with European countries
In our literature review, we retained only studies with IgG antibody testing; we excluded those with IgA or IgM serologies. The 11.5% prevalence of IgG in our HCWs is similar to the reported prevalences in Belgium or the United Kingdom (Table 1). Different protective measures, date of blood screening, and/or population structure in each country could explain the variation in IgG serology from 1.6% reported by Korth et al 2 up to 14.5% reported by Bampoe et al. 3 In our hospital, masks are compulsory, and protective equipment has been available since March 17.
Of the 233 HCWs participants with RT-PCR positive, 29 (12.4%) have no detectable antibodies. This result parallels that of Garcia-Basteiro et al, 4 who also reported 15% of individuals with positive RT-PCR and negative serology. A recent study by Patel et al 5 showed the possibility of decreased antibodies over 60 days, which implies transiently detectable antibodies.
Our study has some limitations. During the lockdown period, some HCWs were isolated at home on a case-by-case basis for reasons of severe personal or familial comorbidities. RT-PCR swab tests were conducted at the time of suspected illness only in symptomatic or in individuals who had had contact with COVID-19 patients. Thus, 902 of 4,607 (19.6%) had this test at the time of onset of symptoms.
The detection of asymptomatic cases by RT-PCR is essential to isolating or avoiding quarantine of HCWs to prevent risk of contamination for vulnerable patients and to reduce the risk of interprofessional staff-to-staff transmission.
To limit virus transmission, we emphasize the necessity of large-scale screening for exposed HCWs, even those who do not present any symptoms. Further investigations are needed to explore negative serology in subjects with positive RT-PCR for understanding population immunity and the potential risks of reinfection and disease in HCWs.